1 / 20

Education in Palliative and End-of-life Care - Oncology

The. EPEC-O. TM. Education in Palliative and End-of-life Care - Oncology. Project. The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong Foundation.

justina-day
Download Presentation

Education in Palliative and End-of-life Care - Oncology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The EPEC-O TM Education in Palliative and End-of-life Care - Oncology Project The EPEC-O Curriculum is produced by the EPECTM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong Foundation.

  2. EPEC – Oncology Education in Palliative and End-of-life Care – Oncology Module 3e Symptoms –Bowel Obstruction

  3. Bowel obstruction . . . • Definition: mechanical or functional obstruction of the progress of food and fluids through the GI tract

  4. . . . Bowel obstruction • Impact: misery from nausea, vomiting and abdominal pain

  5. . . . Bowel obstruction Epidemiology • Prevalence • 3 % of all advanced malignancies • 11 – 42 % ovarian cancer • 5 – 24 % colorectal cancer • Prognosis – poor if inoperable • 64 days Krebs HR, Goplerud DR. Am J Obstet Gynecol, 1987. Ripamonti S, et al. J Pain Symptom Manage, 2000.

  6. Key points • Pathophysiology • Assessment • Management

  7. Pathophysiology . . . • Intraluminal mass • Direct infiltration • External compression • Carcinomatosis • Adhesions • Other

  8. . . . Pathophysiology • 2 liters / day orally • 8 liters / day gastric & intestinal secretions • Obstruction causes accumulation • Peristalsis causes distention, pain, nausea, and vomiting

  9. Assessment • Symptoms • Continuous distension pain 92 % • Intestinal colic 72 – 76 % • Nausea/vomiting 68 – 100 % • Abdominal radiograph • Dilated loops, air-fluid levels • CT scan • Staging, treatment planning

  10. Differentiating small vs. large bowel obstruction

  11. Management . . .Medical • Opioids • Morphine – 89 % control • Antiemetics • Prochlorperazine – 13 % control • Steroids • Dexamethasone

  12. . . . ManagementSurgical • Surgical evaluation • Standard • Intravenous fluids • Nasogastric tube – intermittent suction • Inoperable • Stent placement • Venting gastrostomy

  13. Antisecretory agents

  14. Anticholinergics • Antispasmodic and antisecretory • Scopolamine • 10 – 100 mcg / hr SC / IV • 0.1 mg SC q 6 h and titrate • Glycopyrrolate • 0.2 - 0.4 mg SC q 2 – 4 h and titrate Baines M, et al. Lancet, 1985. Davis MP, Furste A. J Pain Symptom Manage, 1999.

  15. Somatostatin • 14 amino acid polypeptide • Serum half-life = 3 minutes • Central action • Inhibits release of GH and thyrotropin • Peripheral action • Inhibits glandular secretion • Pancreas, GI tract

  16. Octreotide . . . • Polypeptide analog of somatostatin • Serum half-life = 2 hr • Relieves symptoms of obstruction Ripamonti, et al. J Pain Symptom Manage, 2000. Mercadante, et al. Supportive Care Cancer, 2000. Fainsinger RL, et al. J Pain Symptom Manage, 1994.

  17. . . . Octreotide • Octreotide 10 mcg/h continuous infusion • Titrate to complete control of N / V • If NG tube in place, clamp when volume diminishes to 100 cc and remove if no N / V • Try convert to intermittent SC • Continue until death

  18. . . . Octreotide • Side effects • Mostly none • Dry mouth • Biliary sludge / stones • Studies in other palliative care settings • Subcutaneous administration

  19. Conclusions • Considerable symptom control challenge • Surgery for selected cases • Pharmacological management relieves symptoms in many patients • Antisecretory agents represent a significant advance

  20. Summary Use comprehensive assessment and pathophysiology-based therapy to treat the cause and improve the cancer experience

More Related